Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28320815 | 0.84 | — | — | |
| SCHEMBL27678854 | 0.81 | LMNA (0.38) | LMNACYP2C9 | |
| SCHEMBL23043822 | 0.76 | LMNA (0.42) | LMNACYP2C9 | |
| SCHEMBL31711888 | 0.76 | — | — | |
| SCHEMBL18407144 | 0.72 | LMNA (0.39) | LMNACYP2C9 | |
| SCHEMBL18407146 | 0.71 | LMNA (0.38) | LMNACYP2C9 | |
| SCHEMBL27450024 | 0.69 | SMN1; SMN2 (0.36) | LMNACYP2C9 | |
| SCHEMBL18407150 | 0.69 | LMNA (0.37) | LMNACYP2C9 | |
| SCHEMBL1746287 | 0.69 | — | — | |
| SCHEMBL18407149 | 0.68 | LMNA (0.36) | LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346332-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LEBER'S HEREDITARY OPTIC NEUROPATHY | IMBRIA PHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20200140375-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH ALTERED TCA CYCLE METABOLISM | IMBRIA PHARMACEUTICALS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20120129787-A1 | Modified oligopeptides with anticancer properties and methods of obtaining them | MARTYNOV ARTUR (UA) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346332-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LEBER'S HEREDITARY OPTIC NEUROPATHY | PRPH, CLN6, PMP22 | TSHR 4823/4885LMNA 125/4885CYP2C9 4666/4885 |
| US-20200140375-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH ALTERED TCA CYCLE METABOLISM | PC, CPS1, FH | TSHR 4481/4885LMNA 2027/4885CYP2C9 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.